November 22, 2019 — Artificial intelligence can examine electrocardiogram (ECG) test results, a common medical test, to pinpoint patients at higher risk of developing a potentially dangerous irregular heartbeat (arrhythmia) or of dying within the next year, according to two preliminary studies to presented at the American Heart Association’s Scientific Sessions 2019 — November 16-18 in Philadelphia. 

Dorothy and Lloyd Huck Chair of Cardiovascular Medicine
Morristown Medical Center/Atlantic Health System 
Professor of medicine, Sidney Kimmel Medical College, Thomas Jefferson University

 

Now, more than ever, the field of cardiology needs women. 


There were a few key takeaways from the American Society of Nuclear Cardiology (ASNC) 2019 annual meeting in September, these included...



Interest in distal radial artery access (DRA) is growing rapidly. Among the benefits of DRA are the low risk of entry site bleeding complications and the low rate of radial artery occlusion.[1,2] This is an overview of the benefits of using distal radial vascular access in the area of the anatomical snuff box in the cath lab. 
 

Faster Hemostasis With Distal Radial Access


November 21, 2019 — At the American Heart Association Scientific Sessions 2019, Eko, a digital health company applying artificial intelligence (AI) and machine learning in the fight against heart disease, presented results in collaboration with

November 21, 2019 — People who experience cardiac arrests over the weekend are less likely to survive long enough to be admitted to a hospital, compared to those who had the same medical event on a weekday, according to preliminary research to be presented at the American Heart Association’s Resuscitation Science Symposium 2019 — November 16-17 in Philadelphia. 

November 21, 2019 — Endotronix, a digital health and medical technology company dedicated to advancing the treatment of chronic heart failure (HF), presented positive first-in-human data of the Cordella Pulmonary Artery (PA) Pressure Sensor System. Data was presented at the 2019 American Heart Association (AHA) scientific sessions by Prof. Dr. Wilfried Mullens of the Hospital Oost-Limburg in Genk, Belgium.

Associate Director, Resynchronization and Advanced Cardiac Therapeutics Program
Massachusetts General Hospital 

It’s an exciting time in the heart failure (HF) world right now with the emergence of new therapies, including medications and devices. Several of these were highlighted in sessions at the 2019 American Heart Association (AHA) scientific sessions.

Subscribe Now